Isomorphic Labs says its November 17 Series C was co-led by Greenoaks and Sequoia Capital. Funds will support IsoDDE, drug candidates and R&D infrastructure. Reported positive results are largely preclinical; human safety and efficacy still need validation.
Synced examines CataX's proposed clinical-development organization, with one lead coordinating specialist agents, external experts and quality review. The Mithril example remains preclinical; organizational efficiency is distinct from human efficacy and safety.
INFevo discloses a pre-A round exceeding RMB 100 million for model R&D, research products and team development. The report describes OCOO-T's experimental metrics and platform plans; results apply to the stated datasets and tasks, not clinical efficacy.
The study evaluates diagnostic and treatment strategies for 40 unpublished complex cases. Scores improved when 250 doctors used the system, but the results do not establish real treatment outcomes.